Small bowel permeability in patients with cytostatic therapy

Kohout, Pavel; Cerman, Jaroslav; Brátová, M; Zadák, Z

doi:10.1016/s0899-9007(99)00113-6

Cited by 22 publications

(18 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the present study, we examined intestinal permeability in patients presenting with stomatitis, in contrast to prospective studies of patients administered a given regimen of chemotherapy (Parilli et al 1989;Sundstrom et al 1998;Kohout et al 1999). Our data demonstrate a marked elevation of intestinal permeability to lactulose, lactulose/mannitol, and lactulose/xylose ratios coincident with the manifestation of stomatitis after chemotherapy.…”

Section: Discussionmentioning

confidence: 73%

“…Intestinal permeability was assessed by measurement of urinary lactulose, D-xylose, and mannitol after oral challenge as described (Kohout et al 1999). Brie¯y, after an overnight fast, patients ingested 100 ml of the test solution containing 2 g of mannitol, 2 g of D-xylose, 10 g of lactulose, and 11 g of glucose in water.…”

Section: Measurement Of Intestinal Permeabilitymentioning

confidence: 99%

“…The percentages of the ingested dose excreted in the urine may vary considerably because of extraintestinal factors (e.g., sampling or excretion), but the calculation of the ratios corrects for these factors (reviewed in Uil et al 1997). The lactulose/ mannitol index is used most frequently to assess intestinal permeability and values above 0.04 are considered abnormal (Kohout et al 1999). …”

Section: Measurement Of Intestinal Permeabilitymentioning

confidence: 99%

“…In clinical situations, functional tests evaluating the barrier function of intestinal mucosa by measuring the absorption of sugars are more practical (Bjarnason et al 1995;Uil et al 1997). An increase in mucosal permeability to lactulose, or decrease in the absorption of D-xylose was reported after cytotoxic therapy (Parrilli et al 1982(Parrilli et al , 1989Bow et al 1997;Keefe et al 1997;Sundstrom et al 1998;Kohout et al 1999).…”

Section: Introductionmentioning

confidence: 98%

See 3 more Smart Citations

Intestinal permeability in patients with chemotherapy-induced stomatitis

Melichar¹,

Kohout²,

Brátová³

et al. 2001

Journal of Cancer Research and Clinical Oncology

Self Cite

View full text Add to dashboard Cite

Lactulose excretion after oral challenge, lactulose/mannitol, or lactulose/xylose ratio may be useful markers for intestinal involvement in chemotherapy-induced mucositis. Improvement of oral mucositis was associated with a significant decrease of intestinal permeability to lactulose. Testing of intestinal permeability by the present method may be useful to evaluate the effect of therapeutic interventions in patients with chemotherapy-induced mucositis.

show abstract

Section: Discussionmentioning

confidence: 73%

Section: Measurement Of Intestinal Permeabilitymentioning

confidence: 99%

Section: Measurement Of Intestinal Permeabilitymentioning

confidence: 99%

Section: Introductionmentioning

confidence: 98%

See 2 more Smart Citations

Intestinal permeability in patients with chemotherapy-induced stomatitis

Melichar¹,

Kohout²,

Brátová³

et al. 2001

Journal of Cancer Research and Clinical Oncology

Self Cite

View full text Add to dashboard Cite

show abstract

“…22 Previously, intestinal function in many diseased states has been measured by absorption of xylose, which is passively absorbed in the jejunum. [23][24][25][26] However, this test has been shown to be variable, and has not been adopted for routine assessment of small intestinal function. 24 Further advancements have led to the combination of disaccharide/monosaccharide sugar permeability tests in which man-made sugar probes are utilized.…”

Section: Methods For Assessing Small Intestinal Functionmentioning

confidence: 99%

Mucositis and non-invasive markers of small intestinal function

Tooley

Howarth²,

Butler³

2009

Cancer Biology & Therapy

View full text Add to dashboard Cite

Mucositis is a common and debilitating side effect of chemotherapy that manifests due to the inability of chemotherapy agents to discriminate between normal and neoplastic cells. This results in ulcerating lesions lining the gastrointestinal tract. Moreover, the development of efficacious treatments for small intestinal mucositis has been hindered as the pathobiology of mucositis is still not fully understood. The small intestine is an extensive organ which is largely inaccessible by conventional means. Non-invasive biomarkers such as small intestinal permeability, H 2 breath tests, serum citrulline tests and the 13 C-sucrose breath test (SBT) have emerged as potential markers of small intestinal function. The SBT is emerging as the more appropriate biomarker to assess chemotherapy-induced mucositis in cancer patients and animal models, where it measures the decrease in sucrase activity associated with villus blunting and crypt disruption. The SBT has been successfully applied to detect mucositis induced by different classes of chemotherapy agents and has been used successfully to monitor small intestinal function with a range of candidate anti-mucositis treatments. We propose the SBT a superior biomarker of small intestinal function that could be successfully applied in clinical practice for monitoring the development of mucositis in cancer patients undergoing chemotherapy.

show abstract

Confirmation and Prevention of Intestinal Barrier Dysfunction and Bacterial Translocation Caused by Methotrexate

et al. 2006

View full text Add to dashboard Cite

When intestinal barrier function is damaged bacterial translocation (BT) can occur. The injury to intestinal barrier function caused by chemotherapy has been investigated in some studies, however, definitive evidence of BT caused by chemotherapy is lacking. The aim of this study was to investigate small intestinal barrier dysfunction and BT and to evaluate the preventive effect of granulocyte colony-stimulating factor (G-CSF) on intestinal barrier dysfunction and BT in a rat model of chemotherapy. Sprague-Dawley rats were treated with methotrexate (MTX; 3.5 mg/kg) for 3 days to induce intestinal barrier dysfunction and BT, gavaged Escherichia coli TG1 labeled with green fluorescent protein for 2 days to track BT, and G-CSF (10 microg/kg) for 4 days to prevent intestinal barrier dysfunction and BT. Intestinal permeability was measured by the urinary excretion rate of lactulose and mannitol following administration by gavage. Representative tissue specimens from the mesenteric lymph nodes, spleen, liver, and kidney were aseptically harvested for bacteria culture in ampicillin-supplemented medium. Light microscopy was performed on intestinal samples. MTX induced significant mucosal and villous atrophy in ileum and significantly increased intestinal permeability. MTX also induced noticeable BT. G-CSF significantly increased the mucosal thickness and villous height of the ileum and decreased intestinal permeability and BT. In conclusion, MTX caused intestinal barrier dysfunction and BT, and G-CSF prevented intestinal barrier dysfunction and BT.

show abstract

Small bowel permeability in patients with cytostatic therapy

Cited by 22 publications

References 15 publications

Intestinal permeability in patients with chemotherapy-induced stomatitis

Intestinal permeability in patients with chemotherapy-induced stomatitis

Mucositis and non-invasive markers of small intestinal function

Confirmation and Prevention of Intestinal Barrier Dysfunction and Bacterial Translocation Caused by Methotrexate

Contact Info

Product

Resources

About